This is the first time Lim has publicly mentioned the situation directly.
“All the excitement about ‘Hanmi legend’ and inexperienced workers led to the situation,” he said.
The drug maker came under fire for making official disclosures belatedly on terminating its license partnerships with Boehringer Ingelheim and Sanofi in July and November, respectively.
Hit by such missteps and other license deal setbacks, Hanmi shares have plunged over 60 percent in the past six months.
Lim urged his employees to restore trust by adhering to basic principles.
“Commitment is important to cooperate with global pharmaceutical companies to develop new drugs,” he said.
By Park Han-na (firstname.lastname@example.org)